Efficacy Assessment of Ultrasound Guided Lauromacrogol Injection for Ablation of Benign Cystic and Predominantly Cystic Thyroid Nodules.
ablation
lauromacrogol
nodules
thyroid
ultrasound
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2019
2019
Historique:
received:
25
01
2019
accepted:
16
04
2019
entrez:
30
5
2019
pubmed:
30
5
2019
medline:
30
5
2019
Statut:
epublish
Résumé
To assess the efficacy and safeness of ultrasound guided lauromacrogol injection for ablation of benign cystic and predominantly cystic thyroid nodules. From July 2016 to July 2018, 102 patients with 107 nodules were treated with ultrasound guided lauromacrogol injections for ablation and 43 nodules completed at least 12 months follow-up. Nodules sonographic characteristics, volume changes before and after USG-LIA, and complications were evaluated. Mean nodule volume decreased from 17.27 ± 20.51 ml to 5.35 ± 14.68ml ( Ultrasound guided lauromacrogol injection for ablation is an effective and safe treatment modality in both purely cystic and predominantly cystic thyroid nodules.
Sections du résumé
BACKGROUND
BACKGROUND
To assess the efficacy and safeness of ultrasound guided lauromacrogol injection for ablation of benign cystic and predominantly cystic thyroid nodules.
METHODS
METHODS
From July 2016 to July 2018, 102 patients with 107 nodules were treated with ultrasound guided lauromacrogol injections for ablation and 43 nodules completed at least 12 months follow-up. Nodules sonographic characteristics, volume changes before and after USG-LIA, and complications were evaluated.
RESULTS
RESULTS
Mean nodule volume decreased from 17.27 ± 20.51 ml to 5.35 ± 14.68ml (
CONCLUSION
CONCLUSIONS
Ultrasound guided lauromacrogol injection for ablation is an effective and safe treatment modality in both purely cystic and predominantly cystic thyroid nodules.
Identifiants
pubmed: 31139077
doi: 10.3389/fphar.2019.00478
pmc: PMC6517687
doi:
Types de publication
Journal Article
Langues
eng
Pagination
478Références
J Clin Endocrinol Metab. 2003 Dec;88(12):5773-7
pubmed: 14671167
Endocr Pract. 2004 May-Jun;10(3):269-75
pubmed: 15310546
Ultraschall Med. 2005 Apr;26(2):142-5
pubmed: 15852178
Eur J Radiol. 2012 May;81(5):905-10
pubmed: 21388767
Eur Radiol. 2012 Jul;22(7):1573-8
pubmed: 22437920
Eur J Radiol. 2013 Feb;82(2):316-20
pubmed: 23159402
Int J Colorectal Dis. 2013 Oct;28(10):1439-47
pubmed: 23775099
Clin Radiol. 2015 Jan;70(1):42-7
pubmed: 25443776
Int Urol Nephrol. 2015 Apr;47(4):603-7
pubmed: 25778818
Pak J Pharm Sci. 2015 Mar;28(2 Suppl):697-700
pubmed: 25796160
Urol Ann. 2015 Jul-Sep;7(3):310-4
pubmed: 26229316
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
BMC Endocr Disord. 2015 Nov 26;15:73
pubmed: 26610707
Endocr Pract. 2016 May;22(5):622-39
pubmed: 27167915
Ann Ital Chir. 2016;87:192-7
pubmed: 27179294
Phlebology. 2018 Apr;33(3):150-162
pubmed: 28166694
Gastrointest Endosc. 2017 Nov;86(5):872-880
pubmed: 28365355
United European Gastroenterol J. 2018 Jul;6(6):919-925
pubmed: 30023070